DAE HWA Pharmaceutical Co., Ltd. (067080.KQ) Stock
DAE HWA Pharmaceutical Co., Ltd.

Company profile
DAE HWA Pharmaceutical reported revenue of 143.06 billion KRW for fiscal year 2025, down 4.2% from fiscal year 2024, and net income of 1.65 billion KRW. That is a net profit margin of 1.2% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 37.03 billion KRW, up 1.0% from a year before. Its largest business segment, Pharmaceutical Manufacturing Industry, brought in 69% of segment revenue in fiscal year 2024; The Republic of Korea was the largest region with 89%. In Q1 2026 it reported a net loss of 245.92 million KRW, against a net loss of 414.10 million KRW a year earlier. Our analysis of its filings shows revenue growing from 141.36 billion KRW in fiscal year 2023 to 143.06 billion KRW in fiscal year 2025, 0.6% a year on average.
What stands out
- Net income more than tripled in fiscal year 2025, from 531.42 million KRW in fiscal year 2024.
Figures from company filings; latest fiscal year ended December 31, 2025.
About DAE HWA Pharmaceutical Co., Ltd.
DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients. The company also exports its products to approximately 22 countries, including Asia, South America, the Middle East, and Africa. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.
Largest shareholders
- Jun-jin Ko9.168 %9.17%
- Soo-Ji Kim9.083 %9.08%
- Woon-Jang Kim3.312 %3.31%
- Han-Gu Lee3.203 %3.20%
- Eun-Seok Kim1.247 %1.25%
Share of the company, as of September 25, 2026
Leadership
- Kim Eun-Seok — CEO & Director, 50
- Byung-Tae No — Chairman & President, 64
- Hye Youn Kim — Director of Development Department
- Byung-Yoon Hwang — Head of Special Sales Division, Head Daegu Division and Senior Managing Director, 70
- Jae-Kwon Yang — Head of Choongang Research Center and Director, 62
How much revenue does DAE HWA Pharmaceutical make?
DAE HWA Pharmaceutical reported 143.06 billion KRW in revenue for fiscal year 2025, down 4.2% from 149.41 billion KRW in fiscal year 2024. In Q1 2026 revenue was 37.03 billion KRW.
What is DAE HWA Pharmaceutical's largest business segment?
Pharmaceutical Manufacturing Industry, with 113.50 billion KRW or 69% of segment revenue in fiscal year 2024. Next: Pharmaceutical Wholesalers (14%) and Pharmaceutical Raw Materials Manufacturing (10%).
Where does DAE HWA Pharmaceutical make most of its revenue?
The Republic of Korea: 89% of revenue by region in fiscal year 2024, followed by Germany (4%).
What companies are similar to DAE HWA Pharmaceutical?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Huons Co., Ltd. (243070.KQ), Reyon Pharmaceutical Co., Ltd. (102460.KS), curacle co.,ltd. (365270.KQ), Daewon Pharmaceutical Co., Ltd. (003220.KS).
Has DAE HWA Pharmaceutical made a profit in recent years?
Net income by fiscal year: FY2021, 2.22 billion KRW; FY2022, 1.12 billion KRW; FY2023, a loss of 1.15 billion KRW; FY2024, 531.42 million KRW; FY2025, 1.65 billion KRW. It reported a net loss in 1 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “DAE HWA Pharmaceutical Co., Ltd. (067080.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/067080.KQ